Jesse Zhu

Also affiliated with Western University, Hospital for Special Surgery, Nanjing Tech University, University of Nottingham Ningbo China, Anhui Agricultural University, Shanghai University of Engineering Science, Guangxi University, Nanjing Normal University, Chongqing University, Tianjin University, Hefei University of Technology, Guizhou University, Jilin University, Anhui Medical University, Tohoku University, China University of Petroleum, Beijing, Sichuan University, China University of Mining and Technology, Wenzhou Medical University, Yunnan Observatories, First Affiliated Hospital of Wenzhou Medical University, Guangxi Normal University, California University of Pennsylvania, Hefei University, West China Second University Hospital of Sichuan University, West China Hospital of Sichuan University, Institute of Applied Ecology, Qingdao Academy of Intelligent Industries, Suzhou Municipal Hospital, Suzhou Research Institute, Forest Research, Jilin Medical University, Collaborative Innovation Center of Advanced Microstructures, Advanced Materials and Devices (United States), Yunnan Environmental Protection Bureau, Changzhou University, Experimental Center of Forestry in North China, Ningbo Institute of Industrial Technology, Nano Carbon (Poland), Ministry of Energy, PRG S&Tech (South Korea), Indiana University School of Medicine, Shandong University of Science and Technology, Newcastle University, Wuhan Sports University, Nanjing University, Texas A&M University, Northeastern University, Tsinghua University

Engineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial”.